-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 2, 2020, Consino Bio announced that it had begun a Phase III clinical trial of the new coronavirus vaccine (Adenovirus 5 vector) ("Ad5-nCoV").
signed an agreement with NPO Petrovax Pharm, LLC ("Petrovax") under which the company and Petrovax will jointly advance phase III clinical trials of Ad5-nCoV in Russia.
and Petrovax have received applications from the Ministry of Health of the Russian Federation for approval of the clinical trial of Ad5-nCoV and have started phase III clinical trials of Ad5-nCoV in Russia.
addition, the company is currently promoting the International Multi-Center Phase III clinical trial of Ad5-nCoV and plans to conduct Phase III clinical trials of Ad5-nCoV in several countries.
.